341 related articles for article (PubMed ID: 22817771)
1. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M
Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
[TBL] [Abstract][Full Text] [Related]
2. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.
Chia KM; Liu J; Francis GD; Naderi A
Neoplasia; 2011 Feb; 13(2):154-66. PubMed ID: 21403841
[TBL] [Abstract][Full Text] [Related]
3. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
4. Prolactin-induced protein in breast cancer.
Naderi A
Adv Exp Med Biol; 2015; 846():189-200. PubMed ID: 25472539
[TBL] [Abstract][Full Text] [Related]
5. Prolactin-induced protein is required for cell cycle progression in breast cancer.
Naderi A; Vanneste M
Neoplasia; 2014 Apr; 16(4):329-42.e1-14. PubMed ID: 24862759
[TBL] [Abstract][Full Text] [Related]
6. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
7. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.
Naderi A; Hughes-Davies L
Neoplasia; 2008 Jun; 10(6):542-8. PubMed ID: 18516291
[TBL] [Abstract][Full Text] [Related]
8. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner.
Baniwal SK; Chimge NO; Jordan VC; Tripathy D; Frenkel B
PLoS One; 2014; 8(6):e62361. PubMed ID: 23755096
[TBL] [Abstract][Full Text] [Related]
9. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M; Dowhan DH
Neoplasia; 2012 Apr; 14(4):283-96. PubMed ID: 22577344
[TBL] [Abstract][Full Text] [Related]
10. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
12. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.
Lehmann-Che J; Hamy AS; Porcher R; Barritault M; Bouhidel F; Habuellelah H; Leman-Detours S; de Roquancourt A; Cahen-Doidy L; Bourstyn E; de Cremoux P; de Bazelaire C; Albiter M; Giacchetti S; Cuvier C; Janin A; Espié M; de Thé H; Bertheau P
Breast Cancer Res; 2013 May; 15(3):R37. PubMed ID: 23663520
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
Naderi A; Liu J
Cancer Lett; 2010 Dec; 298(1):74-87. PubMed ID: 20605569
[TBL] [Abstract][Full Text] [Related]
14. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
15. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
16. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK
Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512
[TBL] [Abstract][Full Text] [Related]
17. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
Moore NL; Buchanan G; Harris JM; Selth LA; Bianco-Miotto T; Hanson AR; Birrell SN; Butler LM; Hickey TE; Tilley WD
Endocr Relat Cancer; 2012 Aug; 19(4):599-613. PubMed ID: 22719059
[TBL] [Abstract][Full Text] [Related]
18. Targeting androgen receptor in estrogen receptor-negative breast cancer.
Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Liu XS; Brown M
Cancer Cell; 2011 Jul; 20(1):119-31. PubMed ID: 21741601
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Zhao L; Liu J; Zhang W; Liu N; Niu Y
Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
[TBL] [Abstract][Full Text] [Related]
20. VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.
Fernández IF; Blanco S; Lozano J; Lazo PA
Mol Cell Biol; 2010 Oct; 30(19):4687-97. PubMed ID: 20679487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]